Lymphoma is a cancer of the lymphatic system. It develops in lymphocytes, which are a type of white blood cell. These cells help fight disease in the body and play an essential role in the body’s immune defenses. It most often spreads to the liver, bone marrow, or lungs. There are two main types of lymphoma: Hodgkin (HL) and non-Hodgkin lymphoma (NHL) (the most common type).

Chemotherapy is often used in the treatment of lymphoma. For some types of lymphoma, chemotherapy drugs are often combined with targeted treatments, such as Rituximab®. It has been noted that NHL becomes progressively chemoresistant while remaining responsive to external beam Radiation therapy. Because of their remarkable effectiveness, radiolabeled tracers and drugs for Imaging and therapy has been approved for use in patients with NHL. These drugs have proven to be remarkably effective and safe.

Sources: Medical News Today,,


90Y-Ibritumomab Tiuxetan (Zevalin®) (Non-Hodgkin’s lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL))


177Lu-Lilotomab satetraxetan (Betalutin) (Non-Hodgkin’s lymphoma)

131I-Apamistamab (Iomab-B™) (Acute Myeloid Lymphoma (AML),Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s lymphoma (NHL))

225Ac-L-Lintuzumab (225Ac-Actimab-A™) (Acute Myeloid Lymphoma (AML))

90Y-Basixilimab (Hodgkin Lymphoma – Non-Hodgkin Lymphoma)



Lymphoma – National Cancer Society

Lymphoma; Patient Version – National cancer Institute NIH

Compassionate Use Program (CUP)

CUP enables patients with life-threatening diseases, such as advanced cancer, to resort to experimental treatments when standard anti-cancer solutions and access to clinical trials are not an option. Access to CUP programs depends on local regulations and can vary from one treatment to another.

Ask your referring physicians for more information regarding CUP.